EMA Launches Vaccine Monitoring Project - - BioPharm International


EMA Launches Vaccine Monitoring Project

The European Medicines Agency (EMA) has announced the launch of Accelerated development of vaccine benefit-risk collaboration in Europe (ADVANCE), a vaccine monitoring project. EMA, in collaboration with organizations involved in assessing the benefits and risks of vaccines, expects the project to “deliver a blueprint for a pan-European framework for monitoring the benefits and risks of vaccines throughout their lifecycle, and for communicating these benefits and risks,” according to an EMA press release

According to EMA, efforts to monitor vaccination coverage and the benefits and risks of vaccines after approval have been fragmented, and the goal of ADVANCE is to review, develop, and test methods, data sources, and procedures that will help to provide data for the assessment of vaccines. It is EMA’s hope that the project will provide health professionals, regulatory agencies, public health institutions, and the general public with the information needed to make better decisions regarding the use of vaccines.

The five-year project is supported by the Innovative Medicines Initiative (IMI) and involves EMA, the European Centre for Disease Prevention and Control, pharmaceutical companies, national public health and regulatory bodies, academic experts, and small and medium-sized enterprises. EMA will be responsible for developing and testing guidance that will include methodological standards, governance rules, a code of conduct, and a communication strategy. ADVANCE will be coordinated by the Erasmus Medical Center in the Netherlands and the Children’s Hospital Basel, University of Basel, Switzerland.

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here